Skip to main content
Premium Trial:

Request an Annual Quote

Good Start Genetics Presents Validation Results for NGS Carrier Screening Test

Premium

Good Start Genetics this week presented results from a validation study of its next-generation sequencing-based carrier screening technology at the American Society for Reproductive Medicine annual meeting.

Using proprietary multiplex gene capture, next-gen sequencing, and computational analysis, the researchers analyzed 56 samples containing at least one out of a total of 93 previously characterized disease-causing mutations, according to the meeting abstract. Several of the samples contained two mutations because they were obtained from compound-heterozygous individuals affected by the disease.

The researchers accurately identified all 93 mutations, which are associated with eight genetic disorders: Canavan disease, maple syrup urine disease, cystic fibrosis, glycogen storage disease 1a, Tay-Sachs, familial dysautonomia, mucolipidosis IV, and Niemann-Pick type A.

The company plans to launch its carrier screening test commercially in the first quarter of 2012.

The Scan

Not Yet a Permanent One

NPR says the lack of a permanent Food and Drug Administration commissioner has "flummoxed" public health officials.

Unfair Targeting

Technology Review writes that a new report says the US has been unfairly targeting Chinese and Chinese-American individuals in economic espionage cases.

Limited Rapid Testing

The New York Times wonders why rapid tests for COVID-19 are not widely available in the US.

Genome Research Papers on IPAFinder, Structural Variant Expression Effects, Single-Cell RNA-Seq Markers

In Genome Research this week: IPAFinder method to detect intronic polyadenylation, influence of structural variants on gene expression, and more.